Acacia Pharma initiates phase II study with APD405 in post-operative nausea & vomitting (PONV)
11-Jun-2009 -
Acacia Pharma announced the initiation of a Phase II study of its lead compound, APD405, in the prevention of post-operative nausea & vomiting (PONV). PONV remains a clinically significant problem in patients undergoing major surgery, despite the availability of a range of anti-emetic ...
central nervous system
chemotherapy
dopamine
+5